Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real‐World: Results From the SCORE—Clinical Atherosclerotic Cardiovascular Disease (ASCVD) Study
Authors' conclusion
Semaglutide 2.4 mg was associated with a significantly reduced risk of MACE and other obesity-related outcomes, extending prior evidence of benefits to a broader clinical ASCVD population.
Study context
- Population
- Adults aged ≥ 45 years with overweight/obesity and clinical ASCVD without diabetes, US database (2016–2024)matched cohort
- Participants
- 38,308 vs 76,615
- Exposure
- Semaglutide 2.4 mg vs no semaglutide 2.4 mg
- Semaglutide 2.4 mgn = 38,308
- No semaglutide 2.4 mgn = 76,615reference
- Outcome
- rMACE-3 (MI, stroke, all-cause mortality) and rMACE-5 (rMACE-3, HF hospitalisation, coronary revascularization)
- Follow-up
- Mean 8.6 months
Methodological detailsreal-world, propensity-score matched 1:2
- Real-world
- Propensity-score matched 1:2
Main finding
As reported in the abstract
Semaglutide 2.4 mg vs Not treatedHazard ratio (95% CI)
rMACE-3
0.55(0.47–0.65)
rMACE-5
0.63(0.56–0.71)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | |
|---|---|---|
| MACE-3 and MACE-5 (CV-related mortality) · mean follow-up 8.6 monthsSemaglutide 2.4 mgvs Not treatedMACE-3 | 0.66 (0.56–0.78) | |
| MACE-3 and MACE-5 (CV-related mortality) · mean follow-up 8.6 monthsSemaglutide 2.4 mgvs Not treatedMACE-5 | 0.69 (0.62–0.77) | |
| 0.512Hazard ratio (log scale) |
HF composite outcomes, incident T2D, major adverse kidney events (MAKE) and major obesity-related adverse events (MORAE)
- Semaglutide 2.4 mg significantly reduced the risk of HF composite outcomes, T2D, MAKE and MORAE
Original publication
Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real‐World: Results From the SCORE—Clinical ASCVD Study. Diabetes Obes Metab. Published 26 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →